BridgeBio Pharma, Inc. / Fundamentals
Income statement
- Net revenue
€202.33M - Cost of goods sold
€6.48M - Gross profit
€195.84M - SG&A expenses
€341.92M - R&D expenses
€406.23M - EBITDA
-€552.20M - D&A
-€488.20K - EBIT
-€562.52M - Interest expenses
€113.82M - EBT
-€668.87M - Tax expenses
€4.67M - Net income
-€666.16M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€24.99M - Changes in working capital
€25.93M - Operating cash flow
-€562.68M - Capex
€8.63M - Other investing cash flow
-€9.37M - Net investing cash flow
€17.50M - Total cash dividends paid
€0.00 - Issuance of common stock
-€15.44K - Debt repayment
€686.40M - Other financing cash flow
€35.92M - Net financing cash flow
€718.15M - Foreign exchange effects
€0.00 - Net change in cash
€172.97M - Cash at end of period
€644.44M - Free cash flow
-€554.05M
Balance sheet
- Cash and cash equivalents
€642.99M - Cash and short-term investments
€649.80M - Total receivables
€65.95M - Inventory
€15.68M - Other current assets
€51.30M - Total current assets
€782.73M - Property, plant & equipment
€10.55M - Goodwill
€0.00 - Intangible assets
€25.32M - Long-term investments
€94.12M - Other non-current assets
€14.08M - Total non-current assets
€144.07M - Total assets
€926.80M - Accounts payable
€22.42M - Short-term debt
€8.23M - Other current liabilities
€111.18M - Total current liabilities
€150.88M - Long-term debt
€2.29B - Deferred tax liabilities
€0.00 - Other non-current liabilities
€467.61K - Total non-current liabilities
€2.30B - Total liabilities
€2.45B - Common stock
€169.88K - Retained earnings
-€2.96B - Other equity
€858.00 - Total equity
-€1.53B - Total liabilities and shareholders' equity
€926.80M
Company information
- Market capitalization
€7.27B - Employees
725 - Enterprise Value
€7.08B
Company ratios
- Gross margin
-
96.8% Much better than peer group: -20,080.7% - EBITDA margin
-
-272.9% Much better than peer group: -28,467.8% - EBIT margin
-
-278.0% Much better than peer group: -28,883.9% - EBT margin
-
-330.6% Much better than peer group: -29,683.4% - Net margin
-
-329.3% Much better than peer group: -29,253.4% - ROE
-
43.7% Much better than peer group: -116.3% - ROA
-
-71.9% Much worse than peer group: -50.3% - Asset turnover
-
21.8% Better than peer group: 16.7% - FCF margin
-
-282.4% Much better than peer group: -25,913.1% - FCF yield
-7.9% - Efficiency ratio
372.9% - Net sales per employee
-
€279.07K - Net income per employee
-
-€918.85K